Atezolizumab

– Continued commercial execution drives record total revenues of $1.2 billion (+16% YoY) – – Company raises 2026 revenue guidance – – Prepared to launch Ziihera® in HER2+ 1L GEA immediately following FDA approval – – Xywav® revenues grew 13% YoY with 525 net patient adds in 2Q26 – – Epidiolex® revenues grew 16% YoY – DUBLIN, Aug. 3, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the second quarter of 2026 (2Q26) and raised revenue guidance for 2026. "Our second quarter results highlight strong execution and momentum across the business, delivering 16% year-over-year total revenue growth and driving a considerable increase to our full-year revenue guidance," said Renee Gala, president and chief executive officer of Jazz Pharmaceuticals. "We remain focused on long-term growth as we prepare to launch Ziihera in HER2+ 1L GEA, advance the zanidatamab and Epidiolex clinical programs, and expand our pipeline through targeted corporate development and internal research and development. The combination of commercial execution, portfolio expansion and our strong financial foundation positions Jazz to deliver meaningful innovation for patients and substantial value for shareholders." Recent Key Highlights Highest ever total quarterly revenues of $1.2 billion with 16% year-over-year (YoY) growth. Generated GAAP / non-GAAP1 adjusted earnings per share (EPS) of $2.78 / $5.71 with $824 million in cash from operations in the first half of 2026. U.S. Food and Drug Administration (FDA) granted Priority Review and set Prescription Drug User Fee Act (PDUFA) target action date of August 25, 2026 for supplemental Biologics License Application (sBLA) for zanidatamab containing combinations in first-line (1L) gastroesophageal adenocarcinoma (GEA). Results from Phase 3 HERIZON-GEA-01 published in The New England Journal of Medicine; additional subgroup analyses presented in an oral presentation at the 2026 ASCO Annual Meeting showing improved clinical outcomes with zanidatamab-containing combinations regardless of PD-L1 expression, including in PD-L1-negative patients. FDA granted Breakthrough Therapy designation (BTD) for zanidatamab in adults with previously treated locally advanced, unresectable, or metastatic HER2-positive colorectal cancer (CRC). Following strong 1H26 commercial execution, the company raised its 2026 revenue guidance range to $4.60 - $4.75 billion, reflecting anticipated double-digit YoY revenue growth from both Xywav and the combined epilepsy and oncology franchises. Business Updates Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution: Xywav net product sales increased 13% YoY to $471 million in 2Q26. Robust new patient growth, with approximately 525 net patient adds in 2Q26. There were approximately 17,125 active patients exiting the quarter, comprised of approximately 11,275 narcolepsy patients and approximately 5,850 idiopathic hypersomnia (IH) patients. Continued physician and patient demand for the differentiated benefits of low-sodium Xywav. Epidiolex/ Epidyolex (cannabidiol): Epidiolex/Epidyolex net product sales increased 16% YoY to $292 million in 2Q26, driven by continued strong demand. Expanded Epidiolex development program to reach more patients with the following clinical trials: Phase 3 trial in developmental and epileptic encephalopathy (DEE), Phase 2/3 trial in juvenile myoclonic epilepsy (JME) and Phase 3b/4 trial in adult Lennox-Gastaut syndrome (LGS). Submitted New Drug Application (NDA) for cannabidiol capsule formulation to broaden utilization of cannabidiol in currently approved indications and increase flexibility for patients. Ziihera (zanidatamab-hrii): Ziihera net product sales in biliary tract cancer (BTC) were $15 million in 2Q26. Prepared to launch zanidatamab in HER2+ 1L GEA (PDUFA date of August 25, 2026). Top-line results from the second interim overall survival (OS) analysis for the HERIZON-GEA-01 trial doublet regimen are expected in 3Q26. Modeyso™ (dordaviprone): Modeyso net product sales were $48 million in 2Q26 with more than 600 patients having received Modeyso from product launch in August 2025 through the end of the second quarter of 2026. Anticipate the OS interim analysis for the event-driven Phase 3 ACTION trial in 1H27, based on current pace of event accrual. Zepzelca® (lurbinectedin): Zepzelca net product sales increased 42% YoY to $106 million in 2Q26, driven by continued uptake of the Zepzelca and atezolizumab combination in the 1L maintenance ES-SCLC setting, partially offset by a decline in second-line use. Based on the results from the LAGOON trial of Zepzelca in second-line metastatic SCLC, and in alignment with FDA, in 3Q26, we will submit for FDA's review and subsequent action a labeling supplement to remove the second-line indication. The first-line maintenance indication will not be affected. Corporate Development: Announced a preclinical research collaboration with AbCellera Biologics Inc. (AbCellera), to develop next-generation T-cell engaging multispecific antibodies for multiple gastrointestinal (GI) cancers and other solid tumors. The company continues to actively evaluate additional value-enhancing corporate development. Financial Highlights GAAP and non-GAAP adjusted net income in 2Q26 includes acquired in-process research and development (IPR&D) expense of $77.0 million, relating to upfront payments made in connection with our collaboration and license agreement with AbCellera and asset purchase agreement to acquire remaining rights for JZP898 from Werewolf Therapeutics, Inc. (Werewolf). This impacted our GAAP and non-GAAP adjusted results by $65.4 million (net of tax of $11.6 million) or $0.94 per share. GAAP and non-GAAP adjusted net loss in 2Q25 includes acquired IPR&D expense of $905.4 million representing the value allocated to Modeyso in the Chimerix Acquisition, which impacted our results by $14.78 per share and $14.75 per share on a GAAP and non-GAAP adjusted basis, respectively. Reconciliations of applicable GAAP reported to non-GAAP adjusted information are included at the end of this press release. Total Revenues Total revenues increased 16% in 2Q26 YoY primarily due to higher Xywav, Epidiolex/Epidyolex and Zepzelca net product sales and the inclusion of Modeyso net product sales, following FDA approval in August 2025. Operating Expenses and Income Tax Expense (Benefit) Changes in operating expenses and income tax expense (benefit) in 2Q26 over the prior year period are primarily due to the following: Cost of product sales, on a GAAP and non-GAAP adjusted basis, increased in 2Q26, primarily due to higher royalty expenses, driven by higher revenues of Modeyso and Zepzelca, offset on a GAAP basis, by lower acquisition accounting inventory fair value step up expense. Selling, general and administrative (SG&A) expenses, on a GAAP and non-GAAP adjusted basis, increased in 2Q26, primarily due to higher marketing investment and compensation-related expenses in support of our commercial portfolio. Research and development (R&D) expenses, on a GAAP and non-GAAP adjusted basis, increased in 2Q26, driven by higher clinical studies costs, primarily related to zanidatamab. Acquired IPR&D, on a GAAP and non-GAAP adjusted basis, in 2Q26 comprised the upfront payments to AbCellera and Werewolf. Income tax expense, on a GAAP and non-GAAP adjusted basis, in 2Q26 reflects changes in the geographic mix of income and expenses compared to 2Q25. Cash Flow and Balance Sheet As of June 30, 2026, cash, cash equivalents and investments were $2.2 billion, and the outstanding principal balance of the company's long-term debt was $4.4 billion. In addition, the company had undrawn borrowing capacity under a revolving credit facility of $885 million. In June 2026, we repaid the $1.0 billion aggregate principal amount of the 2.00% exchangeable senior notes due 2026. For the six months ended June 30, 2026, the company generated $824 million of cash from operations reflecting strong business performance and continued financial discipline. 2026 Financial Guidance Jazz Pharmaceuticals has updated its full-year 2026 financial guidance as shown in the table below. Conference Call Details Jazz Pharmaceuticals will host an investor conference call and live audio webcast today at 4:30 p.m. ET to provide a business and financial update and discuss its 2026 second quarter results. Interested parties may register for the call here or via the Investors section of the Jazz Pharmaceuticals website at . To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. A replay of the webcast will be available via the Investors section of the Jazz Pharmaceuticals website at . About Jazz Pharmaceuticals Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is a global biopharma company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with rare disease — often with limited or no therapeutic options. We have a diverse portfolio of medicines, including leading therapies addressing epilepsies, cancers and sleep disorders. Our patient-focused and science-driven approach powers pioneering research and development advancements across our robust pipeline of innovative therapeutics. Jazz is headquartered in Dublin, Ireland with research and development laboratories, manufacturing facilities and employees in multiple countries committed to serving patients worldwide. Please visit for more information. Non-GAAP Financial Measures To supplement Jazz Pharmaceuticals' financial results and guidance presented in accordance with U.S. generally accepted accounting principles (GAAP), the company uses certain non-GAAP (also referred to as adjusted or non-GAAP adjusted) financial measures in this press release and the accompanying tables. In particular, the company presents non-GAAP adjusted net income (loss) (and the related per share measure) and its line-item components, as well as certain non-GAAP adjusted financial measures derived therefrom, including non-GAAP adjusted gross margin percentage and non-GAAP adjusted effective tax rate. Non-GAAP adjusted net income (loss) (and the related per share measure) and its line-item components exclude from GAAP reported net income (loss) (and the related per share measure) and its line-item components certain items, as detailed in the reconciliation tables that follow, and in the case of non-GAAP adjusted net income (loss) (and the related per share measure), adjust for the income tax effect of the non-GAAP adjustments. In this regard, the components of non-GAAP adjusted net income (loss), including non-GAAP adjusted cost of product sales, SG&A expenses and R&D expenses, are income statement line items prepared on the same basis as, and therefore components of, the overall non-GAAP adjusted net income (loss) measure. The company believes that each of these non-GAAP financial measures provides useful supplementary information to, and facilitates additional analysis by, investors and analysts and that each of these non-GAAP financial measures, when considered together with the company's financial information prepared in accordance with GAAP, can enhance investors' and analysts' ability to meaningfully compare the company's results from period to period, to its forward-looking guidance, and to identify operating trends in the company's business. In addition, these non-GAAP financial measures are regularly used by investors and analysts to model and track the company's financial performance. Jazz Pharmaceuticals' management also regularly uses these non-GAAP financial measures internally to understand, manage and evaluate the company's business and to make operating decisions, and compensation of executives is based in part on certain of these non-GAAP financial measures. Because these non-GAAP financial measures are important internal measurements for Jazz Pharmaceuticals' management, the company also believes that these non-GAAP financial measures are useful to investors and analysts since these measures allow for greater transparency with respect to key financial metrics the company uses in assessing its own operating performance and making operating decisions. These non-GAAP financial measures are not meant to be considered in isolation or as a substitute for comparable GAAP measures; should be read in conjunction with the company's consolidated financial statements prepared in accordance with GAAP; have no standardized meaning prescribed by GAAP; and are not prepared under any comprehensive set of accounting rules or principles in the reconciliation tables that follow. In addition, from time to time in the future there may be other items that the company may exclude for purposes of its non-GAAP financial measures; and the company has ceased, and may in the future cease, to exclude items that it has historically excluded for purposes of its non-GAAP financial measures. Likewise, the company may determine to modify the nature of its adjustments to arrive at its non-GAAP financial measures. Because of the non-standardized definitions of non-GAAP financial measures, the non-GAAP financial measures as used by Jazz Pharmaceuticals in this press release and the accompanying tables have limits in their usefulness to investors and may be calculated differently from, and therefore may not be directly comparable to, similarly titled measures used by other companies. Cautionary Note Concerning Forward-Looking Statements This press release contains forward-looking statements, including, but not limited to, statements related to: the company's growth prospects and future financial and operating results, including the company's 2026 financial guidance and the company's expectations related thereto, including with respect to anticipated catalysts; the company's advancement of pipeline programs and the timing of development activities, regulatory activities, approvals, and submissions related thereto; the company's preparation for a near-term commercial launch of zanidatamab in 1L HER2+ GEA in the U.S. following potential approval on or before the PDUFA date; the company's expectations with respect to its regulatory submissions, including its NDA for a cannabidiol oral capsule formulation for potential use in existing approved Epidiolex/Epidyolex formulations; planned or anticipated clinical trial events, including with respect to initiations, enrollment and data read-outs, and the anticipated timing thereof, including: the second interim OS data from the Phase 3 HERIZON trial of zanidatamab in 1L GEA and top-line data from the Phase 3 ACTION trial of Modeyso in recurrent H3 K27M-mutant diffuse glioma; the company's expectations with respect to its preclinical research collaboration, option and license agreement with AbCellera; and the company's development, regulatory and commercialization strategy, including the company's expectation of portfolio expansion through business development and its research and development engine; the company's expectations with respect to its products and product candidates and the potential of the company's products and product candidates and the potential regulatory path related thereto, including zanidatamab's potential to become the HER2-targeted therapy of choice in 1L HER2+ GEA; the company's capital allocation and corporate development strategy; the potential successful future development, manufacturing, regulatory and commercialization activities; the company's ability to realize the commercial potential of its products; the company's net product sales and goals for net product sales from new and acquired products; the company's views and expectations relating to its patent portfolio, including with respect to expected patent protection, as well as expectations with respect to exclusivity; the company's clinical trials confirming clinical benefit or enabling regulatory submissions, including the potential of the ongoing Phase 3 ACTION trial to confirm clinical benefit of Modeyso in recurrent H3 K27M-mutant diffuse glioma and extend to use in 1L patients; and other statements that are not historical facts. These forward-looking statements are based on the company's current plans, objectives, estimates, expectations and intentions and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties associated with: maintaining or increasing sales of, and revenue from, Xywav, Epidiolex/Epidyolex, Ziihera, Modeyso, Zepzelca and other lead marketed products; effectively launching and commercializing the company's other products and product candidates; the successful completion of development and regulatory activities with respect to the company's product candidates; obtaining and maintaining adequate coverage and reimbursement for the company's products; the time-consuming and uncertain regulatory approval process, including the risk that the company's current and/or planned regulatory submissions may not be submitted, accepted or approved by applicable regulatory authorities in a timely manner or at all, including the risk that zanidatamab in 1L HER2+ GEA may not be approved in a timely manner or at all; the costly and time-consuming pharmaceutical product development process and the uncertainty of clinical success, including risks related to failure or delays in successfully initiating or completing clinical trials and assessing patients; global economic, financial, and healthcare system disruptions and the current and potential future negative impacts to the company's business operations and financial results; protecting and enhancing the company's intellectual property rights and the company's commercial success being dependent upon the company obtaining, maintaining and defending intellectual property protection and exclusivity for its products and product candidates; delays or problems in the supply or manufacture of the company's products and product candidates, including due to geopolitical tensions and military conflicts; complying with applicable U.S. and non-U.S. regulatory requirements, including those governing the research, development, manufacturing and distribution of controlled substances; government investigations, legal proceedings and other actions; identifying and consummating corporate development transactions, financing these transactions and successfully integrating acquired products, product candidates and businesses; the company's ability to realize the anticipated benefits of its collaborations and license agreements with third parties; the sufficiency of the company's cash flows and capital resources; the company's ability to achieve targeted or expected future financial performance and results and the uncertainty of future tax, accounting and other provisions and estimates; the company's ability to meet its projected long-term goals and objectives, in the time periods that the company anticipates, or at all, and the inherent uncertainty and significant judgments and assumptions underlying the company's long-term goals and objectives; fluctuations in the market price and trading volume of the company's ordinary shares; and other risks and uncertainties affecting the company, including those described from time to time under the caption "Risk Factors" and elsewhere in the company's Securities and Exchange Commission filings and reports, including the company's Annual Report on Form 10-K for the year ended December 31, 2025 and future filings and reports by the company. Other risks and uncertainties of which the company is not currently aware may also affect the company's forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. Contacts: Investors: [email protected] Ireland +353 1 634 7800 U.S. +1 650 496 2717 Media: [email protected] Ireland +353 1 637 2141 U.S. +1 215 867 4948 21% more press release views with Request a Demo

编者按 2026年9月12日至15日，由国际肺癌研究协会（IASLC）主办的2026世界肺癌大会（WCLC 2026）将在韩国首尔隆重召开。作为全球胸科肿瘤学领域规模最大、影响力最广的学术盛会之一，WCLC每年汇聚来自世界各地的顶尖研究者、临床医生、护士及患者倡导者，共同分享肺癌诊疗领域的前沿进展，推动学科变革与全球合作。本届大会预计吸引超过7,000名国际参会者，设置150余场学术会议与研讨会，展示2,200余篇摘要，内容广泛覆盖肺癌筛查、精准治疗、免疫治疗、围术期管理及转化研究等热点领域。 日前，大会官网公布了部分摘要标题，其中口头报告及迷你口头报告专场共计200余项研究中，有60余项来自中国学者，研究方向涵盖基础转化、临床新药探索、真实世界数据分析及人工智能应用等多个前沿领域，充分彰显了中国肺癌研究的蓬勃活力与国际影响力。为此，《肿瘤瞭望》特整理现已公布的口头报告及迷你口头报告摘要标题，以飨读者。 口头报告 OA01. 支气管镜检查和分期的最新进展 日期：2026.9.13 专场主席：James Huang（美国）、Tracy L. Leong（澳大利亚） 摘要号：OA01.01 标题：In-Vivo Bronchoscopic FLIM Imaging Enables Optical Confirmation and Sampling of Peripheral Lung Lesions: First-in-Human Prospective Study 中文标题：体内支气管镜FLIM成像实现周围型肺病变的光学确认与采样：首项人体前瞻性研究讲者：A.D.L. Marshall（英国） 摘要号：OA01.02 标题：European Real-World Experience With Robotic-Assisted Bronchoscopy and Integrated Cone-Beam CT: Results From the Eurorab Group 中文标题：机器人辅助支气管镜联合一体化锥形束CT的欧洲真实世界经验：Eurorab研究组结果讲者：A. ROSELL（瑞士） 摘要号：OA01.03 标题：Distinguishing Multiple Primary Lung Cancers From Intrapulmonary Oligometastasis Using Whole Genome Sequencing 中文标题：利用全基因组测序区分多原发肺癌与肺内寡转移讲者：T. Park（韩国） 摘要号：OA01.04 标题：Survival Outcomes and Risk Factors for Nodal Upstaging in Clinical Node-Negative NSCLC From a Population-Based Cohort 中文标题：基于人群队列的临床淋巴结阴性NSCLC淋巴结分期上调的生存结局与危险因素讲者：J. Rice（美国） OA02. 精准肿瘤学提升标准：从创新到新标准 日期：2026.9.13 专场主席：Benjamin Besse（法国）、Mónica Adriana Castro（阿根廷） 摘要号：OA02.01 标题：Efficacy and Safety of GFH375 in Advanced KRASG12D Mutant Non-Small Cell Lung Cancer (NSCLC) Patients 中文标题：GFH375在晚期KRASG12D突变型非小细胞肺癌（NSCLC）患者中的疗效与安全性讲者：李子明 教授（上海交通大学医学院附属胸科医院） OA03. 重新思考肺癌筛查——人工智能、公平性和超越传统风险的早期检测 日期：2026.9.13 专场主席：Rudolf M. Huber（德国）、Jacob Sands（德国） 摘要号：OA03.01 标题：Socioenvironmental Determinants of Health and Associations With Sybil AI Risk Scores. 中文标题：健康的社会环境决定因素及其与Sybil人工智能风险评分的关联讲者：E. Garrad（美国） 摘要号：OA03.02 标题：Breathomics-Based Risk Stratification for Pre-imaging Triage of Lung Cancer: A Prospective Multicenter Study 中文标题：基于呼吸组学的肺癌影像检查前分诊风险分层：一项前瞻性多中心研究讲者：郑健琪 教授（广州医科大学附属第一医院） 摘要号：OA03.03 标题：Improving Engagement With Australia’s National Lung Cancer Screening Program: The Ready to Screen Cluster Randomised Implementation Trial 中文标题：提高澳大利亚国家肺癌筛查计划的参与度：Ready to Screen整群随机实施试验讲者：N.M. Rankin（澳大利亚） OA04. 重新定义可切除NSCLC的围术期治疗：整合免疫治疗和分子靶向策略以提高治愈率 日期：2026.9.13 专场主席：Pei-Jye Voon（马来西亚）、Vanessa Costa Menezes（巴西） 摘要号：OA04.01 标题：A Phase III Randomized Multicenter Trial of Adjuvant Gefitinib Plus Chemotherapy Versus Chemotherapy in EGFR-Mutant NSCLC 中文标题：吉非替尼辅助联合化疗对比单纯化疗用于EGFR突变NSCLC的III期随机多中心试验讲者：B-C. AHN（韩国） 摘要号：OA04.02 标题：Final Analysis of the Phase 3 IMpower030 Study: Perioperative Atezolizumab + Chemotherapy in Resectable Stage II-IIIB NSCLC 中文标题：IMpower030 III期研究的最终分析：阿替利珠单抗联合围术期化疗用于可切除II-IIIB期NSCLC讲者：B. Solomon（澳大利亚） 摘要号：OA04.03 标题：Neoadjuvant Divarasib Shows Manageable Safety and Promising Activity in Resectable KRAS G12C+ NSCLC: Updated NAUTIKA1 Data 中文标题：新辅助Divarasiib在可切除KRAS G12C突变阳性NSCLC中显示可控的安全性和令人鼓舞的疗效：NAUTIKA1研究更新数据讲者：J.E. Chaft（美国） OA05. 小细胞肺癌从发现到实践：重新定义治疗标准和下一代靶向治疗 日期：2026.9.13 专场主席：Sofia Baka（希腊）、Rosalyn Juergens（加拿大） 摘要号：OA05.01 标题：Phase 1 Study of LB2102, a dnTGFBR2-armored DLL3-targeted Autologous CAR-T Cell Therapy, in Subjects With Relapsed or Refractory SCLC or LCNEC 中文标题：LB2102（一种dnTGFBR2装甲靶向DLL3自体CAR-T细胞疗法）在复发或难治性SCLC或LCNEC受试者中的I期研究讲者：A. Chiappori（美国） 摘要号：OA05.02 标题：Epigenetic Dysregulation Permits E2F1 Activation-Mediated Neuroendocrine Transformation inEGFR-Mutant Lung Adenocarcinoma 中文标题：表观遗传失调导致EGFR突变型肺腺癌中E2F1激活介导的神经内分泌转化讲者：夏志军 教授（江苏省肿瘤医院） OA06. 跨越社会障碍的肺癌倡导 日期：2026.9.13 专场主席：Takayuki Takahama（日本）、Lillian Leigh（澳大利亚） 摘要号：OA06.01 标题：Low-Grade Doesn’t Mean Low Impact: Patient-Reported Diarrhea and Quality of Life in Lung Cancer 中文标题：低级别不等于低影响：肺癌患者报告腹泻与生活质量讲者：B. King-Kallimanis（美国） 摘要号：OA06.02 标题：The Effect of Oncology Nurse-Led Discharge Planning on Health Outcomes in Lung Cancer Survivors: A Randomized Controlled Trial 中文标题：肿瘤专科护士主导的出院计划对肺癌幸存者健康结局的影响：一项随机对照试验讲者：X. Zhou（重庆大学附属肿瘤医院） 摘要号：OA06.03 标题：Public Perceptions of Lung Cancer: Stigma, Symptom Awareness and Screening Attitudes - Findings From a 2026 Global Survey 中文标题：公众对肺癌的认知：病耻感、症状认知和筛查态度——2026年全球调查结果讲者：J. Fox（英国） 摘要号：OA06.04 标题：Trajectories and Influencing Factors of Perceived Return-To-Work Barriers in Patients After Lung Cancer Surgery: A Longitudinal Cohort Study 中文标题：肺癌术后患者感知返岗障碍的变化轨迹及影响因素：一项纵向队列研究讲者：C. Lei（四川省肿瘤医院） OA07. 肺癌预防新视野：戒烟、空气污染与实施科学 日期：2026.9.14 专场主席：Omotayo Francis Fagbule（尼日利亚）、Sita Andarini（印度尼西亚） 摘要号：OA07.01 标题：Ambient Air Pollution Exposure and Risk of Pleural Mesothelioma: A Prospective Analysis of the UK Biobank 中文标题：环境空气污染暴露与胸膜间皮瘤风险：英国生物银行的前瞻性分析讲者：崔久嵬 教授（吉林大学第一医院） 摘要号：OA07.02 标题：Cytisine for Smoking Cessation in Older Adults: Evidence From the RISP Trial 中文标题：金雀花碱用于老年人戒烟：来自RISP试验的证据讲者：M. Cani（意大利） 摘要号：OA07.03 标题：Ambient Air Pollution Exposure and Lung Cancer Prognosis - Pooled and Comparative Analysis of the International Lung Cancer Consortium 中文标题：环境空气污染暴露与肺癌预后——国际肺癌联盟的汇总与比较分析讲者：R.J. Hung（加拿大） 摘要号：OA07.04 标题：Ambient Air Pollution Exposure and Lung Cancer Prognosis - Pooled and Comparative Analysis of the International Lung Cancer Consortium 中文标题：环境空气污染暴露与肺癌预后——国际肺癌联盟的汇总与比较分析讲者：N.J. Harrison（澳大利亚） OA08. 现代亚肺叶切除术：早期NSCLC的精准手术和非手术策略及STAS的挑战 日期：2026.9.14 专场主席：Paul E. Van Schil（比利时）、Stella Martinez-Jaramillo（哥伦比亚） 摘要号：OA08.01 标题：CT-guided Microwave Ablation vs Lobectomy for Hilar GGO-predominant Nodules: Prospective Multicenter Non-Inferiority Study 中文标题：CT引导下微波消融对比肺叶切除术治疗肺门部磨玻璃影为主结节的前瞻性多中心非劣效性研究讲者：W. Liu（上海交通大学医学院附属仁济医院） 摘要号：OA08.02 标题：Non-Invasive Prediction of Spread Through Air Spaces in Stage I Lung Adenocarcinoma Using CT-based Virtual PET (CPT-STAS): A Multicenter Study 中文标题：基于CT虚拟PET（CPT-STAS）无创预测I期肺腺癌气腔播散：一项多中心研究讲者：翁锚涛 教授（广东省人民医院） 摘要号：OA08.03 标题：Bayesian STAS Prediction for Segmentectomy Planning: Smooth Contour and Nodal Status as Dominant Predictors 中文标题：用于肺段切除术规划的贝叶斯STAS预测：光滑轮廓和淋巴结状态为主要预测因子讲者：S. Ors（土耳其） OA09. 突破边界：不可切除非小细胞肺癌的创新策略 日期：2026.9.14 专场主席：Suresh Senan（荷兰） 摘要号：OA09.01 标题：Effect of Thymosin a-1 on Treatment Completion and Pneumonitis in Chemoradiation Plus Immunotherapy for LA-NSCLC: A Randomized Phase II Trial 中文标题：胸腺肽α1对局部晚期NSCLC放化疗联合免疫治疗中治疗完成率和肺炎的影响：一项随机II期试验讲者：邱波 教授（中山大学肿瘤防治中心） 摘要号：OA09.02 标题：ASTRES: A Phase 2, Single-Arm Study of Atezolizumab in Locally Advanced, Unresectable, Stage III, Non-Small Cell Lung Cancer 中文标题：ASTRES：阿替利珠单抗在局部晚期不可切除III期非小细胞肺癌中的II期单臂研究讲者：E. Felip（西班牙） 摘要号：OA09.03 标题：A Phase 2 Study of JS207, a PD-1/VEGF Bispecific Antibody, Plus Chemotherapy in Patients With Unresectable Stag III NSCLC 中文标题：JS207（一种PD-1/VEGF双特异性抗体）联合化疗在不可切除III期NSCLC患者中的II期研究讲者：吴一龙 教授（广东省人民医院） 摘要号：OA09.04 标题：Stereotactic Radiotherapy in Locally Advanced Non-Small Cell Lung Cancer Unfit for Concurrent Chemoradiation: The STARLORD Study 中文标题：立体定向放疗在不适合同步放化疗的局部晚期非小细胞肺癌中的应用：STARLORD研究讲者：F. Cuccia（意大利） OA10. 新型抗体和ADC——它们是否预示着新基准？ 日期：2026.9.14 专场主席：Alissa Cooper（美国）、Eun Joo Kang（韩国） 摘要号：OA10.01 标题：Phase 1 Global Study of Iza-Bren in Patients With Metastatic EGFR-mutated NSCLC: Results of the Randomized Dose Expansion Cohort 中文标题：Iza-Bren在转移性EGFR突变NSCLC患者中的全球I期研究：随机剂量扩展队列结果讲者：Alexander Spira（美国） 摘要号：OA10.02 标题：Phase II Study of SYS6010 Plus Enlonstobart in Actionable Genomic Alteration (AGA)-Negative Advanced Non-Small Cell Lung Cancer (ANSCLC) 中文标题：SYS6010联合Enlonstobart在可作用基因组变异（AGA）阴性晚期非小细胞肺癌中的II期研究（ANSCLC）讲者：李玮 教授（同济大学附属东方医院） OA11. 肺癌中的循环生物标志物和人工智能驱动生物标志物 日期：2026.9.14 专场主席：Deepali Jain（印度）、Wei-Chin Chang（臺北醫學大學附設醫院） 摘要号：OA11.01 标题：Multi-Omics of ctDNA Shedding Defines Ctnmb Staging and TME Heterogeneity in Early-Stage Lung Cancer 中文标题：循环肿瘤DNA脱落的多组学分析定义早期肺癌的CTNNB1分期及肿瘤微环境异质性讲者：Z. Li（北京大学人民医院） 摘要号：OA11.02 标题：Prioritizing Circulating Proteins for Lung Cancer Risk Stratification Through Integrated Evidence 中文标题：通过整合证据优先筛选循环蛋白用于肺癌风险分层讲者：Zhangyan Lyu（天津医科大学肿瘤医院） 摘要号：OA11.03 标题：Predicting NSCLC Neoadjuvant Immunotherapy Response Using H&E-Derived T-Cell States via Deep Learning 中文标题：基于H&E染色的T细胞状态通过深度学习预测NSCLC新辅助免疫治疗疗效讲者：李东燊 教授（广东省人民医院） 摘要号：OA11.04 标题：Explainable Machine Learning Model to Predict High-Grade Adverse Events in Neoadjuvant Chemo-Immunotherapy for NSCLC: A Multicenter Study 中文标题：可解释机器学习模型预测NSCLC新辅助化学免疫治疗中高级别不良事件：一项多中心研究讲者：F. Zhi（同济大学附属上海市肺科医院） OA12. 超越KRAS：新兴靶点，更智能的联合策略 日期：2026.9.14 专场主席：Benjamin Solomon（澳大利亚）、Antonio Calles（西班牙） 摘要号：OA12.01 标题：Safety and Efficacy of QLC1101 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Harboring KRAS G12D Mutation 中文标题：QLC1101在携带KRAS G12D突变的晚期非小细胞肺癌（NSCLC）患者中的安全性和有效性讲者：熊安稳 教授（同济大学附属东方医院） 摘要号：OA12.02 标题：Efficacy and Safety of HS-10370 Combined With Adebrelimab and Chemotherapy in First-Line Advanced KRAS G12C-Mutated NSCLC 中文标题：HS-10370联合Adebrelimab和化疗一线治疗晚期KRAS G12C突变NSCLC的疗效和安全性讲者：童凡 教授（华中科技大学同济医学院附属同济医院） 摘要号：OA12.03 标题：A Single-Arm Phase 2 Study of First-Line Amivantamab, Lazertinib, Pemetrexed in EGFR-mutant NSCLC: AMIGO-1 (LACOG 0821) 中文标题：埃万妥单抗、兰泽替尼、培美曲塞一线治疗EGFR突变NSCLC的单臂II期研究：AMIGO-1（LACOG 0821）讲者：W.N. William Jr.（巴西） OA13. 耐药、重编程与拓展：从分子到转移的肺癌生物学 日期：2026.9.14 专场主席：Tetsuya Mitsudomi（日本） 摘要号：OA13.01 标题：Intracranial Responders in Cerebrospinal Fluid and Peripheral-Intracranial Immune Linkage During ICI Therapy in NSCLC Brain Metastases 中文标题：NSCLC脑转移患者免疫检查点抑制剂治疗期间脑脊液及外周-颅内免疫联动的颅内应答者讲者：黎扬斯 教授（广东省人民医院） 摘要号：OA13.02 标题：Spatial Transcriptomic and Proteomic Mapping of TROP2 in NSCLC Reveal RNA-protein Discordance and Tumor Microenvironment Associations 中文标题：TROP2在NSCLC中的空间转录组学和蛋白质组学图谱揭示RNA-蛋白质不一致及肿瘤微环境关联讲者：J. Deshane（美国） 摘要号：OA13.03 标题：Extrachromosomal Circular DNA-mediated Evolution in EGFR-mutated Lung Cancer 中文标题：染色体外环状DNA介导的EGFR突变肺癌演化讲者：Jake Lee（美国） 摘要号：OA13.04 标题：Pre-Clinical Characterization of IDP-001, a First-in-Class EGFRxCDCP1 Bispecific Antibody Drug Conjugate for Lung Cancer 中文标题：IDP-001（首创EGFR×CDCP1双特异性抗体药物偶联物）用于肺癌的临床前特征研究讲者：P.M. Holland（美国） OA14. 晚期NSCLC的突破性免疫治疗 日期：2026.9.14 专场主席：James Chih-Hsin Yang（國立台灣大學醫學院附設醫院）、Alona Zer （以色列） 摘要号：OA14.01 标题：RC148 (ABBV-1480, PD-1/VEGF Bispecific Antibody) Plus Chemotherapy in First-Line Locally Advanced or Metastatic Non-Small-Cell Lung Cancer 中文标题：RC148（ABBV-1480，PD-1/VEGF双特异性抗体）联合化疗一线治疗局部晚期或转移性非小细胞肺癌讲者：张力 教授（中山大学肿瘤防治中心） 迷你口头报告 MO01. 重编程战场：肺癌中的免疫微环境、分子开关与新兴疗法 日期：2026.9.13 专场主席：钟文昭 教授（广东省人民医院）、Ferdinando Cerciello（瑞士） 摘要号：MO01.01 标题：IL-18-Driven Inflammatory Networks Define Stage-Specific Vulnerabilities and Inform Lung Precancer Interception 中文标题：IL-18驱动的炎症网络定义分期特异性脆弱性，并为肺癌癌前病变的拦截提供依据讲者：Jianjun Zhang（美国） 摘要号：MO01.02 标题：SPP1A Macrophage Niches Define Divergent NK Cell States Associated With Response to Neoadjuvant Immunotherapy in NSCLC 中文标题：SPP1A巨噬细胞龛定义与NSCLC新辅助免疫治疗疗效相关的不同NK细胞状态讲者：Z. Zhang（同济大学附属上海市肺科医院） 摘要号：MO01.03 标题：A Novel De Novo Engineered SFRP2/PDL1 Bispecific Antibody Boosts the Abscopal Effect of Radioimmunotherapy 中文标题：一种新型从头工程化SFRP2/PD-L1双特异性抗体增强放射免疫治疗的远隔效应讲者：张艳培 教授（南方医科大学第八附属医院） 摘要号：MO01.04 标题：Lung-Targeted mRNA-LNP Delivery of SOX2 Bioprotac: A Comprehensive Strategy for LUAD, LUSC, and SCLC in Monotherapy and Combination Settings 中文标题：肺靶向mRNA-LNP递送SOX2生物PROTAC：用于LUAD、LUSC和SCLC单药及联合治疗的综合性策略讲者：T. Choi（韩国） 摘要号：MO01.05 标题：mSWI/SNF Complex Inhibition Sensitizes KRAS-Mutant Lung Cancers to Targeted Therapies via Epithelial-Mesenchymal Subversion 中文标题：mSWI/SNF复合物抑制通过上皮-间质逆转使KRAS突变肺癌对靶向治疗增敏讲者：W. Jin（美国） 摘要号：MO01.06 标题：Multiomic Spatial Analysis Reveals Immunosuppression During Therapy Resistance and Histological Transformation in EGFR-mutant LUAD 中文标题：多组学空间分析揭示EGFR突变型肺腺癌治疗耐药和组织学转化过程中的免疫抑制讲者：T. Sen（美国） 摘要号：MO01.07 标题：Organoids From Ground-Glass Opacity Reveal a PRO-Invasive Role of THBS2? CAFs in Early-Stage Lung Adenocarcinoma 中文标题：来自磨玻璃结节的类器官揭示THBS2?癌症相关成纤维细胞在早期肺腺癌中的促侵袭作用讲者：Y. Li（上海交通大学） 摘要号：MO01.08 标题：Association of Gut Microbiome Diversity With Survival and Immune-Related Toxicity in Locally Advanced NSCLC 中文标题：肠道微生物多样性与局部晚期NSCLC生存及免疫相关毒性的关联讲者：A. San Martin Doblado（西班牙） 摘要号：MO01.09 标题：Cerebrospinal Fluid Biomarker Profiling in Patients With Non-Small Cell Lung Cancer and Leptomeningeal Disease 中文标题：非小细胞肺癌伴软脑膜转移患者的脑脊液生物标志物谱分析讲者：Mark Jeng（美国） MO02. 老年肺癌的筛查与监测、卫生服务 日期：2026.9.13 专场主席：Ambreen Sayani,（加拿大）、Cs Pramesh（印度） 摘要号：MO02.01 标题：Extended CT Surveillance Beyond 5 Years and Outcomes in Long-Term Lung Cancer Survivors 中文标题：延长至5年以上的CT监测与长期肺癌幸存者的结局讲者：D.W. Yoon（韩国） 摘要号：MO02.02 标题：A Cross-Sectional Evaluation of Guideline-Adherent Screening Eligibility Among Zimbabwean Lung Cancer Patients 中文标题：津巴布韦肺癌患者中指南依从性筛查资格的横断面评估讲者：T.A. Mazhindu（津巴布韦） 摘要号：MO02.03 标题：California Lung Cancer Screening Trial: Female Asian Never-Smokers With a Family History of Lung Cancer 中文标题：加利福尼亚肺癌筛查试验：有肺癌家族史的女性亚裔从不吸烟者讲者：Michael Ou（美国） 摘要号：MO02.04 标题：Real-World Patterns of Care and Outcomes in Second Primary Lung Cancer 中文标题：第二原发肺癌的真实世界治疗模式和结局讲者：Q. Wang（美国） 摘要号：MO02.05 标题：LET'S SCREEN: Identifying Unmet Social Needs in Patients With Non-Small Cell Lung Cancer 中文标题：LET'S SCREEN：识别非小细胞肺癌患者未满足的社会需求讲者：A.I. Velazquez Manana（美国） 摘要号：MO02.06 标题：Ambulatory Acute Care in Lung Cancer: Experience From a Palliative Care Day Hospital in Colombia 中文标题：肺癌的门诊急性护理：哥伦比亚姑息治疗日间医院的经验讲者：M.P. Uchima-Vera（哥伦比亚） 摘要号：MO02.07 标题：From Implementation to Impact: Outcomes of a Nurse-Led Geriatric Oncology Model of Care (NL-GOMOC) 中文标题：从实施到影响：护士主导的老年肿瘤学照护模式（NL-GOMOC）的结局讲者：N. Knox（澳大利亚） 摘要号：MO02.08 标题：Age ≥80 Is Not a Contraindication to Lung Cancer Treatment: Outcomes in a National VA Cohort 中文标题：年龄≥80岁并非肺癌治疗的禁忌证：全国VA队列中的结局讲者：I.G. Veytsman（美国） 摘要号：MO02.09 标题：Barriers to Enrollment to a Clinical Trial for Frail Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) 中文标题：虚弱晚期非小细胞肺癌（NSCLC）患者入组临床试验的障碍讲者：N.A. Osei（美国） MO03. 从细胞重编程到免疫逃逸：肺癌生物学进展 日期：2026.9.13 专场主席：Puey Ling Chia（新加坡）、Norma Hernandez-Pedro（墨西哥） 摘要号：MO03.01 标题：PTPRD-Driven Neuronal Transdifferentiation Orchestrates an Immunosuppressive Microenvironment in TP53-Mutant NSCLC 中文标题：PTPRD驱动的神经元转分化在TP53突变NSCLC中协调形成免疫抑制微环境讲者：X. Quan（南方医科大学南方医院） 摘要号：MO03.02 标题：Lymph Node Migratory Dendritic Cells Drive Immunosuppressive Remodeling in Early Non-Small Cell Lung Cancer Through the CCL17-CCR4 Axis 中文标题：淋巴结迁移性树突状细胞通过CCL17-CCR4轴驱动早期非小细胞肺癌的免疫抑制重塑讲者：Y. Zhang（天津医科大学总医院） 摘要号：MO03.03 标题：SMARCA4 Deficiency Driving Cancer Stem Cell Transformation Into Pericytes and Mediating Immunotherapy Resistance in Lung Cancer 中文标题：SMARCA4缺陷驱动肺癌干细胞向周细胞转化并介导免疫治疗耐药讲者：X. Zhang（南方医科大学） 摘要号：MO03.04 标题：SLC40A1+ Macrophages Act as Antigen Presenting Cells in EGFR Mutant Patients Exhibiting Resistance to Tyrosine Kinase Inhibitors 中文标题：SLC40A1+巨噬细胞在对酪氨酸激酶抑制剂耐药的EGFR突变患者中充当抗原呈递细胞讲者：Shuxin Zhu（上海交通大学附属胸科医院） 摘要号：MO03.05 标题：Tumor Microenvironment Modeling of LUAD Assembloids Containing iPSC Derived MSC Mediated CAF Heterogeneity 中文标题：包含iPSC来源间充质干细胞介导的CAF异质性的LUAD组装体肿瘤微环境建模讲者：S.G. Gunes（土耳其） 摘要号：MO03.06 标题：Mechanisms of RBM10-Mediated Metabolic-Immune Crosstalk Inbrain Metastasis of EGFR-Mutant Lung Adenocarcinoma 中文标题：RBM10介导的代谢-免疫串扰在EGFR突变型肺腺癌脑转移中的机制讲者：J. Liu（哈尔滨医科大学附属肿瘤医院） 摘要号：MO03.07 标题：GRHL3-Mediated Histone Lactylation Compromises the Blood-Brain Barrier and Facilitates Brain Metastasis in Lung Adenocarcinoma 中文标题：GRHL3介导的组蛋白乳酸化破坏血脑屏障并促进肺腺癌脑转移讲者：Z. Sun（南京医科大学） 摘要号：MO03.08 标题：Lung-Targeted Nebulized CXCL10 mRNA Nanoparticles Enhance CAR-T Therapy in Lung Cancer 中文标题：肺靶向雾化CXCL10 mRNA纳米颗粒增强CAR-T在肺癌中的治疗讲者：B. Xiao（北京大学肿瘤医院） 摘要号：MO03.09 标题：An Atlas of Early Stage ALK+ Lung Adenocarcinoma Reveals a Human-Specific Respiratory Bronchiole Progenitor Signature and Niche Remodeling 中文标题：早期ALK+肺腺癌图谱揭示人特异性呼吸性细支气管祖细胞特征及微环境重塑讲者：Yusoo Lee（美国） MO04. 胸腺恶性肿瘤和胸膜间皮瘤的新型疗法与分子见解 日期：2026.9.13 专场主席：Cecilia Brambilla（英国） 摘要号：MO04.01 标题：Prognostic Impact of Stage, Histology, and Treatment Strategy in 1,026 Thymic Epithelial Tumors: Report From Thymic Registry 中文标题：分期、组织学类型和治疗策略对1026例胸腺上皮肿瘤的预后影响：Thymic注册研究报告讲者：M. Ganzinelli（意大利） 摘要号：MO04.02 标题：Relevant Trial: Updated Survival Outcomes of Ramucirumab in Combination With Chemotherapy in Untreated Advanced Thymic Carcinoma 中文标题：相关试验：雷莫西尤单抗联合化疗用于未经治疗的晚期胸腺癌的更新生存结局讲者：Claudia Proto（意大利） 摘要号：MO04.03 标题：Spatial Transcriptomics Reveals the Potential Mechanism Promoting Immune Exclusion and Chemoresistance in Thymic Carcinoma 中文标题：空间转录组学揭示胸腺癌中促进免疫排斥和化疗耐药的潜在机制讲者：Yi-Ting Yen（台湾成功大学附属医院） 摘要号：MO04.04 标题：Investigating the Diagnostic and Disease Status Monitoring Potential of Circular RNA Biomarkers for Pleural Mesothelioma 中文标题：环状RNA生物标志物用于胸膜间皮瘤诊断和疾病状态监测潜力的研究讲者：B. Johnson（澳大利亚） 摘要号：MO04.05 标题：Enriched Germline Variants in Patients With Mesothelioma Identified by Whole Exome Sequencing in a Cohort of 336 Individuals 中文标题：在336例间皮瘤患者队列中通过全外显子测序发现的富集胚系变异讲者：Alexandre Burdzy（美国） 摘要号：MO04.06 标题：Multi-Platform ctDNA Profiling in Mesothelioma Reveals Superior Detection With a Whole-Genome Informed Approach 中文标题：间皮瘤中多平台ctDNA分析揭示全基因组指导方法具有更优的检测能力讲者：Shohei Waller（美国） 摘要号：MO04.07 标题：Phase II Study of Perioperative Pembrolizumab Plus Neoadjuvant Platinum-Pemetrexed in Resectable Pleural Mesothelioma (CHIMERA Study) 中文标题：帕博利珠单抗围术期联合新辅助铂类-培美曲塞用于可切除胸膜间皮瘤的II期研究（CHIMERA研究）讲者：Giulia Pasello（意大利） 摘要号：MO04.08 标题：Tumour Extrinsic Regulation of Neutrophils Sensitize Mesotheliomas to AXL and PD1 Inhibition in MIST3, a Phase II Clinical Trial 中文标题：肿瘤外部调控中性粒细胞使间皮瘤对AXL和PD1抑制增敏——来自II期临床试验MIST3讲者：Dean Fennell（英国） 摘要号：MO04.09 标题：First-Line Pumitamig (PD-L1×VEGF-A Bsab) Plus Chemotherapy in Unresectable Malignant Mesothelioma: Long-Term PFS and OS 中文标题：Pumitamig（PD-L1×VEGF-A双特异性抗体）联合化疗一线治疗不可切除恶性间皮瘤：长期PFS和OS讲者：张良 教授（吉林省肿瘤医院） MO05. 肺癌风险分层与治疗的病理分级和分子谱分析进展 日期：2026.9.14 专场主席：韩昱晨 教授（上海交通大学医学院附属胸科医院）、Wei-Chin Chang（国立台湾大学医学院附属肿瘤医院） 摘要号：MO05.01 标题：Clinicopathologic Characteristics and Histologic Transformation of RB1-Mutant Lung Adenocarcinoma 中文标题：RB1突变型肺腺癌的临床病理特征及组织学转化讲者：R. Zhao（上海交通大学附属胸科医院） 摘要号：MO05.02 标题：Clinical, Pathologic, and Genomic Characteristics of NRAS- or HRAS-Mutant Non-Small Cell Lung Cancer 中文标题：NRAS或HRAS突变型非小细胞肺癌的临床、病理及基因组学特征讲者：Can Cui（美国） 摘要号：MO05.03 标题：Analysis of MTAP Loss Prevalence Between Tissue and Liquid Non-Small Cell Lung Carcinoma Biopsies 中文标题：组织活检与液体活检中非小细胞肺癌MTAP缺失率的比较分析讲者：Christian Rolfo（美国） 摘要号：MO05.04 标题：A Grading System for Invasive Mucinous Adenocarcinoma of the Lung: A Multi-Institutional Study by the IASLC Pathology Committee 中文标题：肺浸润性黏液腺癌的分级系统：IASLC病理学委员会多机构研究讲者：T. Hayashi（日本） 摘要号：MO05.05 标题：The 2025 IASLC Tumor Budding Grade Identifies High-Risk Patients and Predicts Adjuvant Chemotherapy Benefit in Resected Lung SqCC 中文标题：2025年IASLC肿瘤出芽分级可识别高风险患者并预测切除肺鳞癌的辅助化疗获益讲者：T.H. Hong（韩国） 摘要号：MO05.06 标题：Risk Stratification and Surgical Optimization in Lung Adenocarcinoma: Implications of IASLC Grading and Molecular Profiles 中文标题：肺腺癌的风险分层与手术优化：IASLC分级及分子分型的意义讲者：Haojie Si（同济大学附属上海市肺科医院） 摘要号：MO05.07 标题：KRAS G12C Predicts Superior Outcomes With 1L Cemiplimab for Non-Squamous NSCLC With PD-L1 ≥50%: Data From EMPOWER-Lung 1 中文标题：KRAS G12C突变预示PD-L1≥50%的非鳞状NSCLC一线使用西米普利单抗疗效更优：EMPOWER-Lung 1研究数据讲者：D.R. Gandara（美国） 摘要号：MO05.08 标题：Tertiary Lymphoid Structures After Perioperative Chemoimmunotherapy Are Associated With Reduced Disease Progression in NSCLC 中文标题：围术期化学免疫治疗后三级淋巴结构与NSCLC疾病进展减少相关讲者：A. Gil-González（西班牙） 摘要号：MO05.09 标题：Impact of Protein Arginine Methyltransferase 5 (PRMT5) Expression and MTAP Deletion on OS and Immune Cells in NSCLC 中文标题：蛋白质精氨酸甲基转移酶5（PRMT5）表达及MTAP缺失对NSCLC总生存和免疫细胞的影响讲者：Robert Hsu（美国） MO06. 可切除NSCLC围术期治疗中整合靶向治疗的新型精准策略 日期：2026.9.14 专场主席：Terufumi Kato（日本）、Sara Najmeh （加拿大） 摘要号：MO06.01 标题：NAUTIKA1: Primary Analysis of Neoadjuvant Alectinib in Resectable Stage IB-IIIB ALK+ NSCLC 中文标题：NAUTIKA1研究：阿来替尼新辅助治疗可切除IB-IIIB期ALK阳性NSCLC的主要分析讲者：Jay Lee（美国） 摘要号：MO06.02 标题：Firmonertinib for Stage I EGFR-Mutated NSCLC With Multiple Primary Lung Cancer: A Phase II Trial 中文标题：伏美替尼用于伴有多原发肺癌的I期EGFR突变NSCLC：一项II期试验讲者：王烨 教授（江苏省肿瘤医院） 摘要号：MO06.03 标题：Neoadjuvant BNT116 + Cemiplimab + Carboplatin + Paclitaxel in Resectable NSCLC: Preliminary Results From a Phase I Trial 中文标题：BNT116联合西米普利单抗、卡铂和紫杉醇新辅助治疗可切除NSCLC：一项I期试验的初步结果讲者：Rafal Dzadziuszko（波兰） 摘要号：MO06.04 标题：Neoadjuvant Chemo-Immunotherapy vs EGFR-TKI in EGFR-Mutant NSCLC: TP53 as the Predictive Biomarker for Treatment Selection 中文标题：新辅助化学免疫治疗对比EGFR-TKI在EGFR突变NSCLC中的疗效：TP53作为治疗选择的预测生物标志物讲者：F. Wang（广东省人民医院） 摘要号：MO06.05 标题：Role of Multimodal Prehabilitation in Promoting Anti-Tumor Immunity in Lung Cancer 中文标题：多模式预康复在促进肺癌抗肿瘤免疫中的作用讲者：B. Gordon（加拿大） 摘要号：MO06.06 标题：Station-Based Nodal Assessment and Prognosis After Neoadjuvant Immunochemotherapy in Resectable NSCLC 中文标题：可切除NSCLC新辅助免疫化疗后基于站点的淋巴结评估与预后讲者：Q. Zhong（广州医科大学附属第一医院） 摘要号：MO06.07 标题：The DUMAS Trial, Neo-Adjuvant Immunotherapy for Pancoast Tumors 中文标题：DUMAS试验：新辅助免疫治疗用于肺上沟瘤讲者：Mariano Provencio（西班牙） 摘要号：MO06.08 标题：Long-Term Outcomes Following Neoadjuvant SBRT Combined With Immunochemotherapy in Stage II-III NSCLC 中文标题：新辅助SBRT联合化学免疫治疗用于II-III期NSCLC的长期结局讲者：杨弘 教授（中山大学肿瘤防治中心） 摘要号：MO06.09 标题：Role of PET/CT in the Neoadjuvant Chemoimmunotherapy Approach for Resectable NSCLC: Results From the NADIM II and REAL-NADIM Trials 中文标题：PET/CT在可切除NSCLC新辅助化学免疫治疗中的作用：NADIM II和REAL-NADIM试验结果讲者：A.V. Ospina（西班牙） MO07. 转移性非小细胞肺癌的新型免疫治疗策略 日期：2026.9.14 专场主席：Yiqing Huang（新加坡）、Dae Ho E. Lee（韩国） 摘要号：MO07.01 标题：Development of a Shared Neoantigen Peptide Library to Promote Personalized Vaccine Strategy in Patients With Non-Small Cell Lung Cancer 中文标题：共享新抗原肽库的开发以促进非小细胞肺癌患者的个体化疫苗策略讲者：F. Chen（南京鼓楼医院） 摘要号：MO07.02 标题：Characteristics and Outcomes to Immunotherapy in Patients With NSCLC Harboring Class II and III BRAF Alterations 中文标题：携带II类和III类BRAF突变的NSCLC患者免疫治疗的特征和结局讲者：A. Di Federico（美国） 摘要号：MO07.03 标题：Biallelic Inactivation of KEAP1/STK11 Predicts Benefit to Dual PD-(L)1/CTLA4 Immune Checkpoint Blockade in Non-Small Cell Lung Cancers 中文标题：KEAP1/STK11双等位基因失活预测非小细胞肺癌对PD-(L)1/CTLA-4双重免疫检查点阻断的获益讲者：M.Y. Jeng（美国） 摘要号：MO07.04 标题：Gotistobart vs Docetaxel in Metastatic Squamous NSCLC After PD-(L)1 Progression: Updated Overall Survival of the Stage 1 of PRESERVE-003 中文标题：Gotistobart对比多西他赛用于PD-L1经治后进展的转移性鳞状NSCLC：PRESERVE-003研究阶段1的更新总生存讲者：R. Balaraman（美国） 摘要号：MO07.05 标题：Phase 2 Study of Investigational Agents Plus Tislelizumab ± Chemotherapy in Untreated Locally Advanced/Metastatic NSCLC 中文标题：在未经治疗的局部晚期/转移性NSCLC中，研究性药物联合替雷利珠单抗±化疗的II期研究讲者：George Blumenstein（美国） 摘要号：MO07.06 标题：Phase II Study of Opamtistomig (LBL-024), a PD-L1/4-1BB Bispecific Antibody Plus Chemotherapy in First-Line Advanced NSCLC 中文标题：Opamtistomig（LBL-024，一种PD-L1/4-1BB双特异性抗体）联合化疗一线治疗晚期NSCLC的II期研究讲者：黄岩 教授（中山大学肿瘤防治中心） 摘要号：MO07.07 标题：First-in-Human Study of HC010, a Novel PD-1/VEGF/CTLA-4 Trispecific Antibody: Preliminary Results 中文标题：HC010（一种新型PD-1/VEGF/CTLA-4三特异性抗体）的首项人体研究：初步结果讲者：马宇翔 教授（中山大学肿瘤防治中心） 摘要号：MO07.08 标题：Balancing Efficacy and Toxicity in NSCLC Immunotherapy: Multimodal Artificial Intelligence Framework for Dual-Outcome Risk Stratification 中文标题：NSCLC免疫治疗中疗效与毒性的平衡：用于双重结局风险分层的多模态人工智能框架讲者：丁瀚 教授（江苏省肿瘤医院） 摘要号：MO07.09 标题：Peripheral Blood PD-1? Tfh Cells Predict Response and Survival to PD-1 Blockade in Lung Adenocarcinoma 中文标题：外周血PD-1?Tfh细胞预测肺腺癌对PD-1阻断的应答和生存讲者：徐燕 教授（北京协和医院） 摘要号：MO07.10 标题：Updated Efficacy Results of Rilvegostomig for Checkpoint Inhibitor (CPI)-Na?ve Metastatic Non-Small-Cell Lung Cancer (mNSCLC) 中文标题：Rilvegostomig在未经免疫检查点抑制剂（CPI）治疗的转移性非小细胞肺癌（mNSCLC）中的更新疗效结果讲者：Byoung Chul Cho（韩国） MO08. 运动、症状控制与心理支持：迈向更佳结局 日期：2026.9.14 专场主席：Malene Missel（丹麦）、Kaitlyn Gregory（美国） 摘要号：MO08.01 标题：Randomized Trial of a Self-Management Intervention for Patient-Caregiver Dyads in Lung Cancer Surgery 中文标题：肺癌手术中患者-照顾者双人组自我管理干预的随机试验讲者：J.Y. Kim（韩国） 摘要号：MO08.02 标题：Construction and Application of an Empowerment Theory-Based Intervention Program for Learned Helplessness in Elderly Patients With Lung Cancer 中文标题：基于赋权理论的干预方案对老年肺癌患者习得性无助的构建与应用讲者：J-L. Hu（重庆大学附属肿瘤医院） 摘要号：MO08.03 标题：Parallel Stress, Divergent Outcomes: Patient and Caregiver Psychological Distress Following Lung Cancer Surgery 中文标题：并行压力、不同结局：肺癌术后患者与照顾者的心理困扰讲者：Dede Teteh-Brooks（美国） 摘要号：MO08.04 标题：Implementing Scalable Exercise in Lung Cancer Care: Late-Breaking Results From the Randomized LungFit Crossover Trial 中文标题：在肺癌护理中实施可扩展的运动干预：随机LungFit交叉试验的最新突破性结果讲者：Enric Carcereny（西班牙） 摘要号：MO08.05 标题：Community-Based Exercise in Advanced NSCLC: Quality of Life and Biomarker Outcomes From the PRO-ACTIVATE Multicenter Study 中文标题：晚期NSCLC中的社区运动干预：PRO-ACTIVATE多中心研究的生活质量和生物标志物结局讲者：O. Higuer（西班牙） 摘要号：MO08.06 标题：ROAR-LCT: Implementation and Process Evaluation of a Multimodal Virtual Health Intervention for Older Adults With Advanced Thoracic Cancer 中文标题：ROAR-LCT：针对晚期胸部肿瘤老年患者的多模式虚拟健康干预的实施与过程评估讲者：C.J. Presley（美国） 摘要号：MO08.07 标题：In-Hospital ePRO-Based Symptom Management and Functional Recovery After Lung Cancer Surgery: A Secondary Analysis of a Randomized Trial 中文标题：肺癌术后基于院内电子患者报告结局（ePRO）的症状管理和功能恢复：一项随机试验的二次分析讲者：Y. Zhang（四川省肿瘤医院） 摘要号：MO08.08 标题：Temporal Timing of irAEs Modulates Anti-PD-L1 Efficacy-Toxicity Association in Adjuvant and Advanced Treatment of NSCLC 中文标题：免疫相关不良事件（irAEs）的时间发生时机调节抗PD-L1在NSCLC辅助和晚期治疗中的疗效-毒性关联讲者：N. Gao（中山大学孙逸仙纪念医院） 摘要号：MO08.09 标题：Paclitaxel-Induced Neuropathy Prevention With Goshajinkigan in a Lung Cancer-Predominant Population: OLCSG2101 Randomized Phase II Trial 中文标题：牛车肾气丸（Goshajinkigan）预防以肺癌为主的人群中紫杉醇所致神经病变：OLCSG2101随机II期试验讲者：T. Tanaka（日本） MO09. 超越转移：重新定义局部治疗的作用 日期：2026.9.14 专场主席：Dolores Isla（西班牙）、Lilian Faroni（巴西） 摘要号：MO09.01 标题：Concurrent or Consolidative Cranial Stereotactic Radiotherapy in Osimertinib-Treated NSCLC With Limited Brain Metastases 中文标题：奥希替尼治疗伴有假性脑转移的NSCLC中，同时或巩固性颅脑立体定向放疗。讲者：朱正飞 教授（复旦大学附属肿瘤医院） 摘要号：MO09.02 标题：Intracranial Tumour Kinetics in EGFRm NSCLC Treated With Osimertinib, With or Without Upfront Stereotactic Radiosurgery: A STARLET Analysis 中文标题：EGFR突变NSCLC接受奥希替尼治疗（联合或不联合一线立体定向放射外科）的颅内肿瘤动力学。讲者：Cheryl Ho（加拿大） 摘要号：MO09.03 标题：Health Related Quality of Life in EGFRm-mutated Lung Cancer With Brain Metastases: A Joint Analysis of LUOSICNS and OUTRUN Randomized Trials 中文标题：EGFR突变肺癌伴脑转移的健康相关生活质量：LUOSICNS和OUTRUN随机试验的联合分析。讲者：Yu Yang Soon（新加坡） 摘要号：MO09.04 标题：Health-Related Quality of Life With Tumor Treatment (TfT) Therapy Added to Systemic Therapy in Metastatic NSCLC 中文标题：肺癌治疗（TfT）患者全身治疗用于转移性NSCLC的健康相关生活质量。讲者：R. Kotecha（美国） 摘要号：MO09.05 标题：Improved Survival and Disease Control: HITOC Combined With Targeted Therapy in Lung Cancer 中文标题：HITOC联合靶向治疗在伴恶性脑转移的晚期肺癌中改善生存和疾病控制。讲者：罗志林 教授（重庆医科大学附属第三医院） 摘要号：MO09.06 标题：Impact of New-Lesion Progression Risk on Survival Benefit of Local Consolidative Therapy in Immunotherapy-Treated NSCLC 中文标题：新发病灶进展风险对免疫治疗治疗的NSCLC局部巩固治疗生存获益的影响。讲者：H. Chen（复旦大学附属肿瘤医院） 摘要号：MO09.07 标题：Surgery Versus Continued ALK-TKI Therapy in Stage IV ALK-Positive NSCLC: A Propensity Score-Matched Retrospective Study 中文标题：手术对比继续单独ALK-TKI治疗IV期ALK阳性NSCLC：一项倾向性分析匹配回顾性研究。讲者：Z. Li（广东省人民医院） 摘要号：MO09.08 标题：Double Lung Transplantation in Patients With Metastatic Lung-Limited Non-Small Cell Lung Carcinoma (NSCLC): A Case Series 中文标题：双肺移植用于转移性肺癌中局部肺腺癌（NSCLC）患者：病例系列报告。讲者：Young Chae（美国） 摘要号：MO09.09 标题：Thoracic Radiotherapy Exposure and Subsequent Risk of Immune Checkpoint Inhibitor Pneumonitis (ICI-P) 中文标题：胸部放疗暴露及其后免疫检查点抑制剂肺炎（ICI-P）的风险。讲者：E. Adib（美国） MO10. 重新思考肺癌风险：从不吸烟人群到分子、环境和性别视角 日期：2026.9.15 专场主席：Matthew Evison（美国）、Christine D. Berg（美国） 摘要号：MO10.01 标题：Beyond Smoking: Evaluating Environmental Risk Factors and Lung Cancer Screening Eligibility in Central Asia 中文标题：超越吸烟：评估中亚地区环境危险因素与肺癌筛查资格讲者：E. Taioli（美国） 摘要号：MO10.02 标题：Long-Term PM2.5 Exposure and Lung Cancer-Specific Mortality in Patients Who Have Never Smoked Across Two Healthcare Systems 中文标题：长期PM2.5暴露与两个医疗系统中从不吸烟患者肺癌特异性死亡率的关联讲者：T.Y. Lee（美国） 摘要号：MO10.03 标题：Socioeconomic Disparities in Lung Cancer Burden and Radon Testing Across Michigan Counties 中文标题：密歇根州各县肺癌负担与氡检测的社会经济差异讲者：Kaitlin Driesse-Keegan（美国） 摘要号：MO10.04 标题：Impact of Driver Mutations on Survival of Never-Smokers With Lung Cancer: Insights From the Largest Cohort in Europe 中文标题：驱动基因突变对从不吸烟肺癌患者生存的影响：来自欧洲最大队列的见解讲者：Sindhu Naidu（英国） 摘要号：MO10.05 标题：One Mutation, Many Fates: Multi-Region Molecular Profiling Decodes Divergent Trajectories in EGFR-Mutant Never-Smoker Lung Cancer 中文标题：一个突变，多种命运：多区域分子分型揭示EGFR突变型从不吸烟肺癌患者的不同演变轨迹讲者：K. Gupta（新加坡） 摘要号：MO10.06 标题：National Lung Cancer Incidence Among U.S. Persons Who Have Never Smoked 中文标题：美国从不吸烟人群的全国肺癌发病率讲者：D. Srinivasan（美国） 摘要号：MO10.07 标题：Lung Cancer in Women in the MENA Region: An Epidemiological Shift, a GLOBOCAN-Based Longitudinal Study (2012-2022) 中文标题：MENA地区女性肺癌：流行病学转变——基于GLOBOCAN的纵向研究（2012-2022）讲者：K.H. Al-rabi（约旦） 摘要号：MO10.08 标题：Female Sex Is Associated With Improved Survival in ALK-Positive NSCLC: Individual Pooled Data Analysis From Phase 3 Rcts 中文标题：女性性别与ALK阳性NSCLC更优生存相关：来自III期随机对照试验的个体汇总数据分析讲者：H.J. Hoe（美国） 摘要号：MO10.09 标题：ATRX Mutations Are Enriched in Female NSCLC and Associated With Higher Tumor Mutational Burden 中文标题：ATRX突变在女性NSCLC中富集且与更高的肿瘤突变负荷相关讲者：V. Lee（美国） MO11. 肺癌生物标志物发现的创新方法 日期：2026.9.15 专场主席：Jin-Haeng Chung（韩国）、Reinhard Büttner（德国） 摘要号：MO11.01 标题：Deep Driver Mutation Analysis, with/without TP53 in LUAD Using Next-Gen AI of HE Slide-Derived Morphology 中文标题：基于HE染色切片形态学的下一代人工智能进行LUAD中伴/不伴TP53的深度驱动基因突变分析讲者：B. Zhang（德国） 摘要号：MO11.03 标题：Whole-Transcriptome Profiling for the Prediction of Metastatic Recurrence in Patients With Early-Stage Non-Small Cell Lung Cancer 中文标题：全转录组测序用于预测早期非小细胞肺癌患者的转移性复发讲者：R. Borea（美国） 摘要号：MO11.05 标题：Enhanced Detection of Actionable Fusions in NSCLC Using Combined ctDNA and ctRNA Analysis 中文标题：联合ctDNA和ctRNA分析提高NSCLC中可干预融合基因的检测率讲者：C.T. Jani（美国） 摘要号：MO11.06 标题：Nanovesicle Conversion and Multivalent Sensing Enable Sensitive Liquid Biopsy by Overcoming CTC Rarity and Heterogeneity in Lung Cancer 中文标题：纳米囊泡转换和多价传感通过克服肺癌中CTC的稀少和异质性，实现敏感的液体活检讲者：S. Hong（韩国） 摘要号：MO11.07 标题：Integrated Analysis of Lung Microbiome Predicts Response to Anti-PD-1/PD-L1 Immunotherapy in Patients With Non-Small Cell Lung Cancer 中文标题：肺微生物组整合分析预测非小细胞肺癌患者对抗PD-1/PD-L1免疫治疗的应答讲者：L. Wu（广东省人民医院） 摘要号：MO11.08 标题：Beyond PCR: Prognostic Biomarkers in Non-pCR Patients After Neoadjuvant Chemoimmunotherapy for Potentially Resectable Stage IIIA/IIIB NSCLC 中文标题：超越PCR：潜在可切除IIIA/IIIB期NSCLC新辅助化学免疫治疗后非病理学完全缓解患者的预后生物标志物讲者：C. Sun（吉林大学第一医院） 摘要号：MO11.09 标题：Post-Surgical Molecular Residual Disease Detection, Adjuvant Treatment Patterns, and Overall Survival in Resected Stage I-III NSCLC 中文标题：术后分子残留病灶检测、辅助治疗模式及已切除I-III期NSCLC的总生存讲者：C. Aggarwal（美国） MO12. 填补驱动基因改变NSCLC的空白：超越当前边界 日期：2026.9.15 专场主席：王洁 教授（中国中医科学院肿瘤医院）、Alex Adjei（美国） 摘要号：MO12.01 标题：Safety, Pharmacokinetics, and Preliminary Antitumor Activity of VRN110755 in EGFR-Mutated NSCLC 中文标题：VRN110755在EGFR突变NSCLC中的安全性、药代动力学及初步抗肿瘤活性讲者：Myung-Ju Ahn（韩国） 摘要号：MO12.02 标题：Anti-Tumor Activity of BH-30643, a Novel Macrocyclic EGFR TKI, in Patients With Secondary EGFR Resistance Mutations 中文标题：BH-30643（一种新型大环EGFR TKI）在携带EGFR二次耐药突变患者中的抗肿瘤活性讲者：H. Horinouchi（日本） 摘要号：MO12.03 标题：Long-Term Safety of Lorlatinib After 7 Years in CROWN: Kinetics, Management, and Correlations With Efficacy 中文标题：CROWN研究中洛拉替尼7年长期安全性：动力学特征、管理及与疗效的关联讲者：Geoffrey Liu（加拿大） 摘要号：MO12.04 标题：Molecular Landscape of Acquired Resistance to Sebaretinib in HER2-mutant NSCLC: Exploratory Biomarker Analysis of SOHO-01 中文标题：塞瑞替尼在HER2突变NSCLC中获得性耐药的分子图谱：SOHO-01探索性生物标志物分析讲者：Xiuning Le（美国） 摘要号：MO12.05 标题：Acquired Resistance to Zongertinib Treatment in Patients With HER2-Mutant NSCLC: Phase Ib Beamon LUNG-1 Study 中文标题：宗格替尼在HER2突变NSCLC患者中治疗获得性耐药：Ib期Beamon LUNG-1研究讲者：David Planchard（法国） 摘要号：MO12.06 标题：Ivonescimab Plus Chemotherapy for Refractory Leptomeningeal Metastasis After High-Dose EGFR-TKI Failure in EGFR-Mutated NSCLC 中文标题：依沃西单抗联合化疗用于高剂量EGFR-TKI治疗失败后EGFR突变NSCLC难治性软脑膜转移讲者：李晓燕 教授（北京天坛医院） 摘要号：MO12.07 标题：160mg Furmonertinib for EGFR-Mutated NSCLC With Leptomeningeal Metastases: A Prospective Single-Arm Study 中文标题：高剂量（160mg）伏美替尼用于EGFR突变NSCLC伴软脑膜转移：一项前瞻性单臂研究讲者：Y. Wang（浙江大学医学院附属第一医院） 摘要号：MO12.08 标题：A Pivotal Phase II Study of Ficonalkib, a 3rd-Generation ALK-TKI, in Advanced ALK-Positive NSCLC After 2nd-Generation ALK-TKI Failure 中文标题：Ficonalkib（一种第三代ALK-TKI）在第二代ALK-TKI治疗失败的晚期ALK阳性NSCLC中的关键II期研究讲者：石远凯（中国医学科学院肿瘤医院） 摘要号：MO12.09 标题：Subcutaneous Amivantamab + Lazertinib With Supportive Care in EGFRm NSCLC: Longer Follow-Up From the Pragmatic COPERNICUS Study 中文标题：皮下注射埃万妥单抗联合兰泽替尼及支持治疗用于EGFR突变NSCLC：COPERNICUS实用性研究的更长期随访讲者：Balazs Halmos（美国） MO13. 肺癌管理中的全球挑战与解决方案 日期：2026.9.15 专场主席：Rohan Patel（美国）、Nikolina Dodlek（塞浦路斯） 摘要号：MO13.01 标题：Impact of Immunotherapy Shortage on Survival in Stage IV NSCLC During the Lebanese Economic Crisis 中文标题：黎巴嫩经济危机期间免疫治疗短缺对IV期NSCLC患者生存的影响讲者：Arafat Tfayli（美国） 摘要号：MO13.02 标题：Global Productivity Losses From Premature Lung Cancer Mortality: A Modeling Study Across 185 Countries 中文标题：过早肺癌死亡导致的全球生产力损失：一项覆盖185个国家的模型研究讲者：N. Libonati（加拿大） 摘要号：MO13.03 标题：Simplified Trials, Broader Reach: Lessons From SWOG S2302 Pragmatica-Lung 中文标题：简化试验，更广覆盖：SWOG S2302 Pragmatica-Lung研究的经验教训讲者：M. Khalil（美国） 摘要号：MO13.04 标题：The Somatic and Germline Mutational Landscape in Young- and Average-Onset Non-Small Cell Lung Cancer (NSCLC) 中文标题：早发与平均发病年龄非小细胞肺癌（NSCLC）的体细胞和胚系突变图谱讲者：Katherine Smith（美国） 摘要号：MO13.05 标题：Real-World Uptake and Outcomes of Adjuvant Osimertinib in EGFR-mutated NSCLC and Impact of TP53 Co-Mutations 中文标题：EGFR突变NSCLC中辅助奥希替尼的真实世界应用及结局，以及TP53共突变的影响讲者：Stephanie Saw（新加坡） 摘要号：MO13.06 标题：A Triage-Aware Neuro-Symbolic Platform for Safe Lung Cancer Trial Matching 中文标题：一种分诊感知的神经符号平台用于安全的肺癌临床试验匹配讲者：Vittoria Peppoloni（意大利） 摘要号：MO13.07 标题：Accuracy and Safety of AI-generated Summaries in Lung Multidisciplinary Cancer Conferences: A Prospective Pilot Study 中文标题：AI生成的摘要用于肺癌多学科癌症会议中的准确性与安全性：一项前瞻性初步研究讲者：L. Thanabalachandran（加拿大） 摘要号：MO13.08 标题：AI-based Detection of New, Relevant Pulmonary Findings on Radiotherapy Planning CT Scans in Patients With Lung Cancer 中文标题：基于AI的肺癌放疗计划CT扫描中新发相关肺部病灶的检测讲者：Asabi Leliveld（荷兰） 摘要号：MO13.09 标题：Prevalence of Immunotherapy (IO) Biomarkers, Tumor Microenvironment (TME) Composition and Survival by Race/Ethnicity in NSCLC 中文标题：按种族/民族划分的NSCLC中免疫治疗（IO）生物标志物、肿瘤微环境（TME）组成及生存率的差异讲者：Robert Hsu（美国） MO14. 拓展肺癌筛查——人工智能、可及性与真实世界影响 日期：2026.9.15 专场主席：Sang-Won Um（韩国）、Milena Cavic（塞尔维亚） 摘要号：MO14.01 标题：EU-Wide Estimates of the Burden of Lung Cancer, Screening Eligibility and CT-Capacity Needs 中文标题：欧盟范围内肺癌负担、筛查资格及CT容量需求的估计讲者：Katarina Bartekova（荷兰） 摘要号：MO14.02 标题：When Will Australia See a National NSCLC Stage Shift? Population Modelling of Lung Cancer Screening 中文标题：澳大利亚何时能实现全国性的NSCLC分期变化？肺癌筛查的人群模型预测讲者：Yue He（澳大利亚） 摘要号：MO14.03 标题：Third Brazilian Early Lung Cancer Trial (BRELT3): Initial Results of Mobile Lung CT Screening in Low Resources Setting 中文标题：第三项巴西早期肺癌试验（BRELT3）：资源匮乏环境下移动肺CT筛查的初步结果讲者：R. Sales Santos（巴西） 摘要号：MO14.04 标题：Comparison of Lung Cancer Screening Outcomes Between Family History and Smoking Risks: Results From the TNLCEDP 中文标题：基于家族史与吸烟风险的肺癌筛查结果比较：TNLCEDP研究结果讲者：L.J. Lin（臺北市政府衛生局） 摘要号：MO14.05 标题：Precision Prevention in Action: Results From the INTERCEPTION-Lung Screening and Prevention Program 中文标题：精准预防在行动：INTERCEPTION-Lung筛查与预防项目的结果讲者：Pamela Abdayem（法国） 摘要号：MO14.06 标题：Comparison of Sybil Artificial Intelligence With Lung-RADS for Lung Cancer Detection on Low-Dose CT Screening 中文标题：Sybil人工智能与Lung-RADS在低剂量CT筛查中用于肺癌检测的比较讲者：M. Naghavi（美国） 摘要号：MO14.07 标题：Artificial Intelligence-Based Lung Cancer Risk Prediction From Cardiac CT in Smokers and Non-Smokers: A Heartlung Study Within the MESA 中文标题：基于人工智能的心脏CT在吸烟者和非吸烟者中预测肺癌风险：MESA研究中的Heartlung研究讲者：M. Mozafary（美国） 摘要号：MO14.08 标题：Artificial Intelligence (AI) Driven Incidental Pulmonary Nodule (IPN) Programs Diagnosed More Lung Cancer Patients Than LDCT Screening 中文标题：人工智能（AI）驱动的偶发性肺结节（IPN）项目比LDCT筛查诊断出更多肺癌患者讲者：Luis Raez（美国） 摘要号：MO14.09 标题：Mortality Reduction in a Broader High-Risk Population: Results From China Lung Cancer Screening (CLUS) Version 1.0 With 10-Year Follow-Up 中文标题：在更广泛高危人群中降低死亡率：中国肺癌筛查（CLUS）1.0版10年随访结果讲者：钱芳 教授（上海交通大学医学院附属胸科医院） MO15. 拓展SCLC治疗前沿：ADC、T细胞衔接器和一线策略 日期：2026.9.15 专场主席：Naoki Furuya（日本）、Isabella Favato Barcelos（巴西） 摘要号：MO15.01 标题：CXCL9+DCs and CXCR3+ Tregs Drive Neoadjuvant Chemoimmunotherapy Resistance in Limited-Stage SCLC 中文标题：CXCL9+树突状细胞与CXCR3+调节性T细胞驱动局限期小细胞肺癌新辅助化学免疫治疗耐药讲者：王海永 教授（山东第一医科大学附属肿瘤医院） 摘要号：MO15.02 标题：A Phase 2 Trial of QLC5508 (MHB088C) Plus QL1706 or QL2107 as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer 中文标题：QLC5508（MHB088C）联合QL1706或QL2107一线治疗广泛期小细胞肺癌的II期试验讲者：X. Chen（同济大学附属东方医院） 摘要号：MO15.03 标题：Pathological Response and MRD Dynamics After Neoadjuvant Serplulimab Plus Chemotherapy in Stage IIB-IIIB (N2) LS-SCLC 中文标题：斯鲁利单抗联合化疗新辅助治疗IIB-IIIB（N2）期局限期SCLC后的病理学缓解和MRD动态变化讲者：Z. Chen（广东省人民医院） 摘要号：MO15.04 标题：First-Line YL201 Plus Serplulimab in ES-SCLC and Advanced NSCLC: Phase 1 Results of a B7-H3-Directed Combination Strategy 中文标题：YL201联合斯鲁利单抗一线治疗广泛期SCLC和晚期NSCLC：一项靶向B7-H3联合策略的I期结果讲者：赵洪云 教授（中山大学肿瘤防治中心） 摘要号：MO15.05 标题：Expression and Prognostic Impact of B7-H3 in Patients With Extensive-Stage Small-Cell Lung Cancer 中文标题：B7-H3在广泛期小细胞肺癌患者中的表达及预后影响讲者：Stephen Liu（美国） 摘要号：MO15.06 标题：Chemoresistant SCLC Shows SLFN11-Driven Vulnerability to Antibody-Drug Conjugates in Combination With ATR Inhibition 中文标题：化疗耐药SCLC中SLFN11驱动的对抗体药物偶联物联合ATR抑制的易感性讲者：K. Schelch（奥地利） 摘要号：MO15.07 标题：Subcutaneous (SC) Tarlatamab in Patients With Extensive-Stage Small Cell Lung Cancer (ES-SCLC): DeLLphi-308 Phase 1B Study 中文标题：皮下注射塔拉妥单抗用于广泛期小细胞肺癌（ES-SCLC）患者：DeLLphi-308 IB期研究讲者：P. Rocha（西班牙） 摘要号：MO15.08 标题：Dynamic Granulocyte Turnover Inferred From cfDNA Methylation Predicts Immunotherapy Benefit in Liver-Metastatic Small-Cell Lung Cancer 中文标题：基于cfDNA甲基化推断的粒细胞动态更新预测肝转移性小细胞肺癌的免疫治疗获益讲者：王慧 教授（山东省肿瘤医院） 摘要号：MO15.09 标题：Baseline CT-Derived Imaging Biomarkers Predict Risk of Neurotoxicity and Cytokine Release Syndrome With Tarlatamab in ES-SCLC 中文标题：基线CT衍生的影像学生物标志物预测广泛期SCLC接受塔拉妥单抗治疗时神经毒性和细胞因子释放综合征的风险讲者：Lukas Delasos（美国） MO16. 早期NSCLC的精准手术决策——个体化手术时代淋巴结清扫、切缘和风险分层的优化 日期：2026.9.15 专场主席：Nuria Maria Novoa（西班牙）、Yashiro Tsutani（日本） 摘要号：MO16.01 标题：Optimal Extent of Lymphadenectomy (OL) for Resection of NSCLC in IASLC 9th Edition Database 中文标题：IASLC第9版数据库中NSCLC切除术最佳淋巴结清扫范围（OL）讲者：C-F.J. Yang（美国） 摘要号：MO16.02 标题：Lobe-Specific vs No Mediastinal Lymph Node Dissection in Segmentectomy for Stage I NSCLC: Supplementary Analysis of JCOG1211 中文标题：肺段切除术治疗I期NSCLC中叶特异性纵隔淋巴结清扫与不清扫的比较：JCOG1211的补充分析讲者：K. Onodera（日本） 摘要号：MO16.03 标题：Sleeve Resection vs Pneumonectomy in NSCLC: Survival Benefit by Age, Nodal Status, and Resection Completeness 中文标题：NSCLC中袖式切除与全肺切除术比较：按年龄、淋巴结状态和切除完整性分层的生存获益讲者：T. Schneider（德国） 摘要号：MO16.04 标题：Routine Minimally Invasive Thoracic Surgery Without Aspirin Withdrawal: A Prospective, Single-Center, Single-Arm Phase 2 Clinical Study 中文标题：不中断阿司匹林的常规微创胸外科手术：一项前瞻性、单中心、单臂II期临床研究讲者：Y. Zhao（山东大学齐鲁第二医院） 摘要号：MO16.05 标题：Lobar-Specific Limitations of Surgical Margins After Complex Segmentectomy 中文标题：复杂肺段切除术后切缘的肺叶特异性限制讲者：T. Isaka（日本） 摘要号：MO16.06 标题：Margin Benchmark for Adequate Local Control in ≤2 cm Nodal Negative Invasive Lung Adenocarcinoma Sublobar Resection 中文标题：亚肺叶切除治疗≤2cm淋巴结阴性浸润性肺腺癌中实现充分局部控制的切缘基准讲者：Z. Yang（美国） 摘要号：MO16.07 标题：Mutation-Based Risk Stratification and Immunogenomic Features of Nodal Metastasis in Stage T1 Lung Adenocarcinoma 中文标题：T1期肺腺癌淋巴结转移的基于突变的风险分层及免疫基因组学特征讲者：吴芳 教授（中南大学湘雅二医院） 摘要号：MO16.08 标题：Prognostic Value of the IASLC Grading System in Pathologic Stage I Lung Adenocarcinoma Presenting as Subsolid Nodules 中文标题：IASLC分级系统在表现为亚实性结节的病理I期肺腺癌中的预后价值讲者：X. Xinjie（同济大学附属上海市肺科医院） 摘要号：MO16.09 标题：Prognostic Impact of Tumor Centrality and Relationship to Pathologic Aggressiveness in Early NSCLC 中文标题：早期NSCLC中肿瘤中心性及其与病理侵袭性关系的预后影响讲者：J.Y. Kim（韩国） 内容来源：WCLC 官网  https://wclc.iaslc.org 排名不分先后 按照摘要类别划分 如有遗漏或任何问题 请后台留言 （来源：《肿瘤瞭望》编辑部） 声 明 凡署名原创的文章版权属《肿瘤瞭望》所有，欢迎分享、转载。本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。